Biohaven is progressing its Graves' disease program by enrolling patients in a pivotal Phase 3 trial of BHV-1300, the first extracellular protein degrader targeting the disease-causing autoantibody. This therapy aims to remove the root cause of Graves' disease, unlike traditional treatments that only manage symptoms. The company also presented new research on patient experiences and autoimmune biology at the 2026 American Thyroid Association meeting. Additionally, Biohaven expanded its technology reach through a licensing deal in Asia, supporting further development and global access.
Biohaven's Graves' disease research progress is noted here with Pluang's Health-sector market data as of Nov 05, 2026 19:01 WIB: Of 150 priced Health-sector US stocks tradable on Pluang, 94 rose and 48 fell today. Notable movers include MESO at USD 14.79 (+3.50%), EW at USD 102.74 (+3.39%) with a Pluang order activity skewed 85% Sell / 15% Buy, and LFST at USD 14.67 (+3.24%). MESO showed the highest daily gain among these.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
